Zacks: Brokerages Expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to Announce -$0.74 Earnings Per Share

Brokerages expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to report ($0.74) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Kala Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.79) and the highest is ($0.70). Kala Pharmaceuticals posted earnings of ($0.60) per share during the same quarter last year, which indicates a negative year over year growth rate of 23.3%. The firm is scheduled to report its next earnings report on Thursday, August 8th.

On average, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($2.86) per share for the current fiscal year, with EPS estimates ranging from ($3.03) to ($2.71). For the next year, analysts anticipate that the company will report earnings of ($1.86) per share, with EPS estimates ranging from ($2.48) to ($0.58). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.75). The company had revenue of $1.39 million for the quarter, compared to analyst estimates of $0.96 million.

Several analysts have weighed in on the company. Wedbush set a $51.00 price objective on Kala Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 5th. Oppenheimer started coverage on Kala Pharmaceuticals in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. Zacks Investment Research lowered H&E Equipment Services from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, BidaskClub lowered Zogenix from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Kala Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $19.43.

NASDAQ:KALA traded down $0.16 on Friday, hitting $5.57. 90,971 shares of the stock were exchanged, compared to its average volume of 202,293. The firm has a market capitalization of $194.13 million, a PE ratio of -2.29 and a beta of 2.02. Kala Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $14.45. The company has a quick ratio of 9.93, a current ratio of 10.30 and a debt-to-equity ratio of 0.86. The business has a 50-day moving average of $5.79.

In other news, Director Howard B. Rosen purchased 5,000 shares of Kala Pharmaceuticals stock in a transaction on Thursday, May 30th. The stock was purchased at an average price of $5.42 per share, with a total value of $27,100.00. Following the transaction, the director now directly owns 8,240 shares in the company, valued at approximately $44,660.80. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 30.77% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new position in Kala Pharmaceuticals during the 1st quarter valued at approximately $325,000. Alambic Investment Management L.P. purchased a new position in shares of Kala Pharmaceuticals in the 1st quarter worth $344,000. Boston Partners purchased a new position in Kala Pharmaceuticals during the first quarter valued at $152,000. Rhumbline Advisers lifted its position in Kala Pharmaceuticals by 27.4% during the first quarter. Rhumbline Advisers now owns 19,430 shares of the company’s stock valued at $161,000 after purchasing an additional 4,174 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC purchased a new position in Kala Pharmaceuticals during the first quarter valued at $46,000. 69.92% of the stock is owned by institutional investors.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Recommended Story: Can systematic risk be avoided?

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.